Kathryn Packman

6.6k citations

65 papers · 3.9k indexed · 2 hit papers · h-index 28

Impact in

Oncology top 1%
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
Molecular Biology top 2%
- Ubiquitin and proteasome pathways
- Melanoma and MAPK Pathways
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research

Papers in

Oncology 47
- Cancer-related Molecular Pathways 17
- CAR-T cell therapy research 8
- Cancer Treatment and Pharmacology 6
Molecular Biology 40
- Ubiquitin and proteasome pathways 11
- Melanoma and MAPK Pathways 10
- PI3K/AKT/mTOR signaling in cancer 6

Co-authors: Brian Higgins Christian Tovar Kenneth Kolinsky David Heimbrook Zoran Filipovic Lyubomir T. Vassilev Binh Thanh Vu Bradford Graves
Journals: Cancer Research (15 papers)Molecular Cancer Therapeutics (10 papers)Journal of Clinical Oncology (5 papers)Blood (5 papers)ACS Medicinal Chemistry Letters (3 papers)
Partner nations: United States Switzerland Belgium

In The Last Decade

Kathryn Packman

64 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development 2013 · 447 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Journal of Medicinal Chemistry
2006 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Kathryn Packman

Since Specialization

Citations

This map shows the geographic impact of Kathryn Packman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn Packman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn Packman more than expected).

Fields of papers citing papers by Kathryn Packman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathryn Packman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn Packman. The network helps show where Kathryn Packman may publish in the future.

Co-authors

The 25 scholars most cited alongside Kathryn Packman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kathryn Packman Line = papers co-authored together Kathryn Packman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models Blood ·Kodandaram Pillarisetti, Danlin Yang, Leopoldo Luistro, Jianhong Yao, Melissa Smith, 吉則和泉, James Testa, 马力涛, Scott R. Brodeur, YU Chang-zhi, Kathryn Packman, Sanjaya Singh, Ricardo M. Attar, Yusri Elsayed, Ulrike Philippar	2025	3
2	144 (PB132): JNJ-79032421 is a novel membrane restricted mesothelin targeting Tcell engaging bispecific antibody for treatment of mesothelin-positive cancers European Journal of Cancer ·Karine Smans, Samaikya Akarapu, S. De Breuker, Jim Pietrzak, Masaki Narahara, Cristina Danna Steuck, Katrin Sproesser, Shih-Hsiang Chen, Kathryn Packman, Joy Fisher, Siti Aisyah Mohammad Taupik, Ted Petley, Esther W. Chan, رسميه عياد الجهني, О.О. Несен, Matthew V. Lorenzi, Sheri L. Moores, Jeff Clawson, Sylvie Laquerre	2024	0
3	Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors Molecular Cancer Therapeutics ·Linda A. Snyder, Rajendra N. Damle, Shefali Patel, Bruno Raphael, Irene Palias, 宋宗约, L. Setton, Burcu Donat, Carol D. Manning, H.A. El-Hakim, Akiko Akita, Kathryn Packman, Rao N. V. S. Mamidi	2022	4
4	Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer Molecular Cancer Therapeutics ·Jonathan R. Branch, Tammy L. Bush, Vineet Pande, Peter J. Connolly, Zhuming Zhang, Ian Hickson, Giselli C. Domiciano, Steffen Jaensch, James R. Bischoff, Ali Siti Adlina Mat, Game Gayatri Sharad, Lieven Meerpoel, Kathryn Packman, Smaragda Dimitrakopoulou, Yolanda Chong, Marco M. Gottardis, Gilles Bignan	2021	5
5	Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis Molecular Cancer Therapeutics ·Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S. Bushey, Benjamin J. Henley, Su Zhen Hua, Jocelyn Sendecki, Marilda Beqiri, Hillary J. Millar, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre, Sheri L. Moores	2020	138
6	Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach Clinical Cancer Research ·Brian Higgins, Kelli Glenn, Antje‐Christine Walz, Christian Tovar, Zoran Filipovic, K. Vogel, Jesse Drapekin, Kenneth Kolinsky, 啓輔上原, Behrooz Shafiei, Rosario Garrido, Michael Linn, Christophe Meille, David Heimbrook, Lyubomir T. Vassilev, Kathryn Packman	2014	50
7	MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models Cancer Research ·Christian Tovar, Bradford Graves, Kathryn Packman, Zoran Filipovic, J Guiserix, S WAGNER, Rosario Garrido, Jesse Drapekin, Kenneth Kolinsky, Kwong-Him To, Buse Tatar, Frank Podlaski, Peter M. Wovkulich, Binh Thanh Vu, Lyubomir T. Vassilev	2013	220
8	Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation Cancer Research ·Huisheng Wang, Sherif Daouti, Wenhui Li, Wen Yang, Elber Gomes Souza, Brian Higgins, Kathryn Packman, Neal Rosen, John F. Boylan, David Heimbrook, Huifeng Niu	2011	62
9	Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer Cancer Research ·Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su	2011	170
10	Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models Molecular Cancer Therapeutics ·Sherif Daouti, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Huisheng Wang, Elber Gomes Souza, John Moliterni, Nicholas Huby, Nader Fotouhi, Taija Häätylä, Petra Goelzer, Harpreet Sandhu, Jiakui Li, Aruna Railkar, David Heimbrook, Huifeng Niu	2010	23
11	RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models Cancer Research ·Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Raman Iyer, Stanley P. Kolis, Sylvia Zhao, W. Jaskółowski, Joseph F. Grippo, Kathleen Schostack, Mary Ellen Simcox, David Heimbrook, Gideon Bollag, Fei Su	2010	307
12	Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy Cancer Research ·Sherif Daouti, Huisheng Wang, Wenhui Li, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Rafael Soares de Souza Pitombeira, Norman Kong, Nicholas Huby, Wen Yang, Qing Xiang, Frank Podlaski, Yang He, Nader Fotouhi, David Heimbrook, Huifeng Niu	2009	25
13	Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties Cancer Research ·Leopoldo Luistro, Wei He, Melissa Smith, Kathryn Packman, Maria Vilenchik, Daisy Carvajal, John G. Roberts, James J. Cai, Windy Berkofsky‐Fessler, Holly Hilton, Michael Linn, Alexander Flohr, Taís Economides Gallina, Helmut Jacobsen, Kelli Glenn, David Heimbrook, John F. Boylan	2009	154
14	Mesenchymal Stem Cells in Early Entry of Breast Cancer into Bone Marrow PLoS ONE ·Kelly E. Corcoran, Katarzyna A. Trzaska, Helen Fernandes, Margarette Bryan, Marcelo Taborga, R. Molendijk, Kathryn Packman, Prem Patel, Pranela Rameshwar	2008	119
15	Plx4032, a selective b-rafV600E inhibitor has potent anti-tumor activity in b-rafV600E-bearing colorectal xenografts and shows additive effect with other chemoagents Molecular Cancer Therapeutics ·Fei Su, Hong Yang, J. C. Conner, Jianping Chen, Kenneth Kolinsky, Kathryn Packman, David Heimbrook	2007	3
16	Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy Proceedings of the National Academy of Sciences ·Christian Tovar, James Rosinski, Zoran Filipovic, Brian Higgins, Kenneth Kolinsky, Holly Hilton, Xiaolan Zhao, Binh Thanh Vu, Weiguo Qing, Kathryn Packman, Ola Myklebost, David Heimbrook, Lyubomir T. Vassilev Hit paper breakdown →	2006	553
17	Design, synthesis of 1,4-cyclohexyldiamine substituted diaminopyrimidines as selective inhibitors of CDK1, CDK2 and CDK4 and their in vitro and in vivo evaluation Cancer Research ·Qingjie Ding, Nan Jiang, Xin‐Jie Chu, Allen Lovey, Wanda DePinto, Binh Thanh Vu, Suttiruck Buakaew, A. N. Musanov, N. Vogt, John Moliterni, Kathryn Packman, Melissa Smith, 王洋, Bradford Graves, Christine Lukacs, Xuefeng Yin, Yingsi Chen	2005	1
18	Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells Cell Death and Differentiation ·Eline Blix, Kathryn Packman, R. Thurnhofer, Martin Tenniswood	2005	128
19	Antiandrogen-induced cell death in LNCaP human prostate cancer cells Cell Death and Differentiation ·محمدعلی اردکانی, Ping Zhan, Hanatani Yumi, Kathryn Packman, Martin Tenniswood	2003	47
20	Vitamin D3 receptor ablation alters mammary gland morphogenesis Development ·Glendon M. Zinser, Kathryn Packman, JoEllen Welsh	2002	121

About Kathryn Packman

Kathryn Packman is a scholar working on Oncology, Molecular Biology, Hematology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 65 papers that have together received 3.9k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (17 papers), Ubiquitin and proteasome pathways (11 papers), Melanoma and MAPK Pathways (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers), CAR-T cell therapy research (8 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer Treatment and Pharmacology (6 papers) and Prostate Cancer Treatment and Research (6 papers). The work is most often cited by research in Oncology (2.2k citations), Molecular Biology (2.6k citations), Cancer Research (484 citations), Hematology (302 citations) and Biotechnology (219 citations). Kathryn Packman has collaborated with scholars based in United States, Switzerland and Belgium. Frequent co-authors include Brian Higgins, Christian Tovar, Kenneth Kolinsky, David Heimbrook, Zoran Filipovic, Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves, Kelli Glenn and Martin Tenniswood. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Journal of Clinical Oncology, Blood and ACS Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact